Top

Published in:

01-04-2019 | Review

Myeloma light chain cast nephropathy, a review

Authors: Insara Jaffer Sathick, Maria Eleni Drosou, Nelson Leung

Published in: Journal of Nephrology | Issue 2/2019

Abstract

Multiple Myeloma is a plasma cell proliferative disorder that commonly involves the kidney. Renal impairment is a serious complication during the course of the disease that is associated with increased morbidity and mortality. Light chain cast nephropathy is the predominant pattern of renal injury in Multiple Myeloma. This review article focuses on the pathophysiology and diagnostic approach of myeloma cast nephropathy. The management of precipitating factors as well as anti-plasma cell treatment modalities in the context of renal impairment are also discussed.

Kyle RA (1975) Multiple myeloma: review of 869 cases. Mayo Clin Proc 50 (1):29–40

Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J (1994) Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 53(4):207–212CrossRefPubMed

Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E (1998) Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Internal Med 158(17):1889–1893CrossRef

Knudsen LM, Hjorth M, Hippe E (2000) Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65(3):175–181CrossRefPubMed

Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28(33):4976–4984. https://doi.org/10.1200/jco.2010.30.8791 CrossRefPubMed

Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Internal Med 150(8):1693–1695CrossRef

Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, Kohli HS (2000) Renal involvement in multiple myeloma: a 10-year study. Renal Fail 22(4):465–477CrossRef

Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD Jr, Barlogie B (2015) Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia 29(5):1195–1201. https://doi.org/10.1038/leu.2015.15 CrossRefPubMedPubMedCentral

Reule S, Sexton DJ, Solid CA, Chen SC, Foley RN (2016) ESRD due to Multiple Myeloma in the United States, 2001–2010. J Am Soc Nephrol JASN 27(5):1487–1494. https://doi.org/10.1681/asn.2014090876 CrossRefPubMed

10.

Sugihara H, Chihara D, Seike K, Fukumoto K, Fujisawaa M, Suehara Y, Nishida Y, Takeuchi M, Matsue K (2014) Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment. Blood Cancer J 4:e235. https://doi.org/10.1038/bcj.2014.56 CrossRefPubMedPubMedCentral

11.

Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N (2011) Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol JASN 22(6):1129–1136. https://doi.org/10.1681/asn.2010080857 CrossRefPubMed

12.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, Matsouka C, Mparmparousi D, Gika D, Kafantari E, Ziogas D, Fotiou D, Panagiotidis I, Terpos E, Kastritis E (2016) Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol 91(5):499–502. https://doi.org/10.1002/ajh.24335 CrossRefPubMed

13.

Laforet M, Jourde-Chiche N, Haddad F, Sallee M, Stoppa AM, Brunet P, Dussol B, Burtey S, Gondouin B (2016) Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014. Blood Cancer J 6:e409. https://doi.org/10.1038/bcj.2016.17 CrossRefPubMedPubMedCentral

14.

Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, Di Raimondo F, Boccadoro M, Palumbo A, Cavo M (2010) Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 84(3):223–228. https://doi.org/10.1111/j.1600-0609.2009.01385.x CrossRefPubMed

15.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hanel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM (2014) Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 99(1):148–154. https://doi.org/10.3324/haematol.2013.087585 CrossRefPubMedPubMedCentral

16.

Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E (2016) International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 34(13):1544–1557. https://doi.org/10.1200/jco.2015.65.0044 CrossRefPubMed

17.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538-548. https://doi.org/10.1016/s1470-2045(14)70442-5 CrossRef

18.

Ivanyi B (1990) Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 114(9):986–987PubMed

19.

Herrera GA, Joseph L, Gu X, Hough A, Barlogie B (2004) Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128 (8):875–879PubMed

20.

Oshima K, Kanda Y, Nannya Y, Kaneko M, Hamaki T, Suguro M, Yamamoto R, Chizuka A, Matsuyama T, Takezako N, Miwa A, Togawa A, Niino H, Nasu M, Saito K, Morita T (2001) Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 67(1):1–5. https://doi.org/10.1002/ajh.1067 CrossRefPubMed

21.

Pasquali S, Zucchelli P, Casanova S, Cagnoli L, Confalonieri R, Pozzi C, Banfi G, Lupo A, Bertani T (1987) Renal histological lesions and clinical syndromes in multiple myeloma. Renal Immunopathology Group. Clin Nephrol 27(5):222–228PubMed

22.

Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, Lacy M, Dispenzieri A, Rajkumar SV, Kyle RA, Leung N (2012) Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis 59(6):786–794. https://doi.org/10.1053/j.ajkd.2011.12.028 CrossRefPubMed

23.

Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D’Agati VD, Leung N (2012) Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol CJASN 7(2):231–239. https://doi.org/10.2215/cjn.08640811 CrossRefPubMed

24.

Bhutani G, Nasr SH, Said SM, Sethi S, Fervenza FC, Morice WG, Kurtin PJ, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Lacy MQ, Kapoor P, Kumar S, Kyle RA, Rajkumar SV, Leung N (2015) Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 90 (5):587–596. https://doi.org/10.1016/j.mayocp.2015.01.024

25.

Magee C, Vella JP, Tormey WP, Walshe JJ (1998) Multiple myeloma and renal failure: one center’s experience. Renal Fail 20(4):597–606CrossRef

26.

Dingli D, Larson DR, Plevak MF, Grande JP, Kyle RA (2005) Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Diseases 46(2):278–282. https://doi.org/10.1053/j.ajkd.2005.05.004 CrossRef

27.

Kapadia SB (1980) Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine 59(5):380–392CrossRefPubMed

28.

Alexander MP, Nasr SH, Kurtin PJ, Casey ET, Hernandez LP, Fidler ME, Sethi S, Cornell LD (2015) Renal extramedullary hematopoiesis: interstitial and glomerular pathology. Modern Pathol 28(12):1574–1583. https://doi.org/10.1038/modpathol.2015.117 CrossRef

29.

Nasr SH, Preddie DC, Markowitz GS, Appel GB, D’Agati VD (2006) Multiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytes. Kidney Int 69(3):616–620. https://doi.org/10.1038/sj.ki.5000144 CrossRefPubMed

30.

Akilesh S, Alem A, Nicosia RF (2014) Combined crystalline podocytopathy and tubulopathy associated with multiple myeloma. Hum Pathol 45(4):875–879. https://doi.org/10.1016/j.humpath.2013.10.007 CrossRefPubMed

31.

Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Nasr SH (2015) Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87(4):698–711. https://doi.org/10.1038/ki.2014.408 CrossRefPubMed

32.

Landgren O, Kyle RA, Rajkumar SV (2011) From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res 17(6):1243–1252. https://doi.org/10.1158/1078-0432.ccr-10-1822 CrossRefPubMedPubMedCentral

33.

Cohen HJ, Rundles RW (1975) Managing the complications of plasma cell myeloma. Arch Internal Med 135(1):177–184CrossRef

34.

Winearls CG (1995) Acute myeloma kidney. Kidney Int 48(4):1347–1361CrossRefPubMed

35.

Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D’Agati VD (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64(1):281–289. https://doi.org/10.1046/j.1523-1755.2003.00071.x CrossRefPubMed

36.

Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D’Agati VD (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol JASN 12(6):1164–1172PubMed

37.

McCarthy CS, Becker JA (1992) Multiple myeloma and contrast media. Radiology 183(2):519–521. https://doi.org/10.1148/radiology.183.2.1561361 CrossRefPubMed

38.

Kooiman J, Pasha SM, Zondag W, Sijpkens YW, van der Molen AJ, Huisman MV, Dekkers OM (2012) Meta-analysis: serum creatinine changes following contrast enhanced CT imaging. Eur J Radiol 81(10):2554–2561. https://doi.org/10.1016/j.ejrad.2011.11.020 CrossRefPubMed

39.

Moos SI, van Vemde DN, Stoker J, Bipat S (2013) Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radiol 82(9):e387-399. https://doi.org/10.1016/j.ejrad.2013.04.029 CrossRef

40.

Stacul F, Bertolotto M, Thomsen HS, Pozzato G, Ugolini D, Bellin MF, Bongartz G, Clement O, Heinz-Peer G, van der Molen A, Reimer P, Webb JAW (2017) Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines. Eur Radiol. https://doi.org/10.1007/s00330-017-5023-5 CrossRefPubMedPubMedCentral

41.

Bernier GM, Putnam FW (1963) MONOMER–DIMER FORMS OF BENCE JONES PROTEINS. Nature 200:223–225CrossRefPubMed

42.

Bence Jones H (1848) On a new substance occuring in the urine if a patient with mollities ossium. Philos Trans 138:52–62. https://doi.org/10.1098/rstl.1843.0003 CrossRef

43.

Coleman RF, Lupton CH Jr, Mc MJ (1962) Renallesions in inbred mice with plasma-cell tumors. A morphological characterization and histochemical study of the “myeloma kidney” type of lesions which have recently been found to occur in C3H and BALB/C mice carrying transmissible plasma-cell tumors. Arch Pathol 74:6–15PubMed

44.

Solomon A, Weiss DT, Kattine AA (1991) Nephrotoxic potential of Bence Jones proteins. N Engl J Med 324(26):1845–1851. https://doi.org/10.1056/nejm199106273242603 CrossRefPubMed

45.

Baylis C, Falconer-Smith J, Ross B (1988) Glomerular and tubular handling of differently charged human immunoglobulin light chains by the rat kidney. Clin Sci (London: 1979) 74 (6):639–644CrossRefPubMed

46.

Batuman V, Verroust PJ, Navar GL, Kaysen JH, Goda FO, Campbell WC, Simon E, Pontillon F, Lyles M, Bruno J, Hammond TG (1998) Myeloma light chains are ligands for cubilin (gp280). Am J Physiol 275(2 Pt 2):F246–254

47.

Klassen RB, Allen PL, Batuman V, Crenshaw K, Hammond TG (2005) Light chains are a ligand for megalin. J Appl Physiol (Bethesda Md: 1985) 98(1):257–263. https://doi.org/10.1152/japplphysiol.01090.2003 CrossRef

48.

Sanders PW (2012) Mechanisms of light chain injury along the tubular nephron. J Am Soc Nephrol JASN 23(11):1777–1781. https://doi.org/10.1681/asn.2012040388 CrossRefPubMed

49.

Kumar S, Muchmore A (1990) Tamm-Horsfall protein–uromodulin (1950–1990). Kidney Int 37(6):1395–1401CrossRefPubMed

50.

Huang ZQ, Kirk KA, Connelly KG, Sanders PW (1993) Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Investig 92(6):2975–2983. https://doi.org/10.1172/jci116920 CrossRefPubMed

51.

Ying WZ, Sanders PW (2001) Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 158(5):1859–1866. https://doi.org/10.1016/s0002-9440(10)64142-9 CrossRefPubMedPubMedCentral

52.

Serafini-Cessi F, Malagolini N, Cavallone D (2003) Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 42(4):658–676CrossRefPubMed

53.

Sanders PW, Booker BB, Bishop JB, Cheung HC (1990) Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Investig 85(2):570–576. https://doi.org/10.1172/jci114474 CrossRefPubMed

54.

Horton JK, Davies M, Topley N, Thomas D, Williams JD (1990) Activation of the inflammatory response of neutrophils by Tamm–Horsfall glycoprotein. Kidney Int 37(2):717–726CrossRefPubMed

55.

Sengul S, Zwizinski C, Simon EE, Kapasi A, Singhal PC, Batuman V (2002) Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int 62(6):1977–1988. https://doi.org/10.1046/j.1523-1755.2002.00660.x CrossRefPubMed

56.

Basnayake K, Ying WZ, Wang PX, Sanders PW (2010) Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol JASN 21(7):1165–1173. https://doi.org/10.1681/asn.2009101089 CrossRefPubMed

57.

Ying WZ, Wang PX, Aaron KJ, Basnayake K, Sanders PW (2011) Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. Blood 117(4):1301–1307. https://doi.org/10.1182/blood-2010-08-302505 CrossRefPubMedPubMedCentral

58.

Zeisberg M, Neilson EG (2010) Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol JASN 21(11):1819–1834. https://doi.org/10.1681/asn.2010080793 CrossRefPubMed

59.

Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, Rajkumar SV, Dispenzieri A (2009) Screening panels for detection of monoclonal gammopathies. Clin Chem 55(8):1517–1522. https://doi.org/10.1373/clinchem.2009.126664 CrossRefPubMedPubMedCentral

60.

Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA (2005) Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51(5):878–881. https://doi.org/10.1373/clinchem.2004.046870 CrossRefPubMed

61.

McTaggart MP, Lindsay J, Kearney EM (2013) Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients. Am J Clin Pathol 140(6):890–897. https://doi.org/10.1309/ajcp25ihylewcahj CrossRefPubMed

62.

Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97(9):2900–2902CrossRefPubMed

63.

Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, Kumar S, Cha SS, Rajkumar SV, Lacy MQ, Zeldenrust SR, Buadi FK, Hayman SR, Nasr SH, Sethi S, Ramirez-Alvarado M, Witzig TE, Herrmann SM, Dispenzieri A (2012) Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol CJASN 7(12):1964–1968. https://doi.org/10.2215/cjn.11161111 CrossRefPubMed

64.

Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P (2008) Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol CJASN 3(6):1684–1690. https://doi.org/10.2215/cjn.02290508 CrossRefPubMed

65.

Moreau C, Autier B, Cavey T, Rouger E, Norwood J, Bendavid C, Escoffre M, Sebillot M, Decaux O (2016) Evaluation of the impact of renal failure on correlation and concordance between 2 free light chain assays. Clin Lymphoma Myeloma Leukemia 16(12):693–704. https://doi.org/10.1016/j.clml.2016.08.012 CrossRef

66.

Leung N, Behrens J (2012) Current approach to diagnosis and management of acute renal failure in myeloma patients. Adv Chronic Kidney Dis 19(5):297–302. https://doi.org/10.1053/j.ackd.2012.06.001 CrossRefPubMed

67.

Bird JM, Owen RG, D’Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154(1):32–75. https://doi.org/10.1111/j.1365-2141.2011.08573.x CrossRefPubMed

68.

Bridoux F, Delbes S, Sirac C, Pourreau F, Puyade M, Desport E, Jaccard A, Fermand JP, Touchard G (2012) Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress. Presse Medi (Paris: 1983) 41 (3 Pt 1): 276–289. https://doi.org/10.1016/j.lpm.2011.11.008 CrossRef

69.

Ecotiere L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E, Belmouaz S, Quellard N, Kaaki S, Michel Goujon J, Fermand JP, Touchard G, Bridoux F (2016) Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant 31(5):850. https://doi.org/10.1093/ndt/gfw056 CrossRefPubMed

70.

Zand L, Nasr SH, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Kumar S, Kyle RA, Fervenza FC, Sethi S, Dingli D, Rajkumar SV, Kapoor P, McCurdy A, Leung N (2015) Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia Lymphoma 56(12):3357–3364. https://doi.org/10.3109/10428194.2015.1040011 CrossRefPubMed

71.

Soares SM, Fervenza FC, Lager DJ, Gertz MA, Cosio FG, Leung N (2008) Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients. Am J Kidney Dis 52(6):1079–1083. https://doi.org/10.1053/j.ajkd.2008.05.022 CrossRefPubMed

72.

Fish R, Pinney J, Jain P, Addison C, Jones C, Jayawardene S, Booth J, Howie AJ, Ghonemy T, Rajabali S, Roberts D, White L, Khan S, Morgan M, Cockwell P, Hutchison CA (2010) The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol CJASN 5(11):1977–1980. https://doi.org/10.2215/cjn.00650110 CrossRefPubMed

73.

Lorenz EC, Sethi S, Poshusta TL, Ramirez-Alvarado M, Kumar S, Lager DJ, Fervenza FC, Leung N (2010) Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. Nephrol Dial Transpl 25(4):1340–1343. https://doi.org/10.1093/ndt/gfp735 CrossRef

74.

Isaac J, Herrera GA (2002) Cast nephropathy in a case of Waldenstrom’s macroglobulinemia. Nephron 91(3):512–515CrossRefPubMed

75.

Perez NS, Garcia-Herrera A, Rosinol L, Palos L, Santiago E, Espinosa G, Sole M, Campistol JM, Quintana LF (2012) Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transpl 27(1):450–453. https://doi.org/10.1093/ndt/gfr730 CrossRef

76.

Gnemmi V, Leleu X, Provot F, Moulonguet F, Buob D (2012) Cast nephropathy and light-chain deposition disease in Waldenstrom macroglobulinemia. Am J Kidney Dis 60(3):487–491. https://doi.org/10.1053/j.ajkd.2012.01.030 CrossRefPubMed

77.

Santos T, Machado S, Sousa V, Campos M (2015) Cast nephropathy: an extremely rare renal presentation of Waldenstrom’s macroglobulinaemia. BMJ Case Rep 2015. https://doi.org/10.1136/bcr-2015-211210

78.

Adam Z, Stepankova S, Sirotkova A, Cermakova Z, Pour L, Krejci M, Zahradova L, Koristek Z, Lenz J, Hajek R, Vorlicek J, Mayer J (2011) Kidney failure in a patient with chronic B-lymphocytic leukaemia (B-CLL) with underlying cast nephropathy. The value of free immunoglobulin light chain identification for early diagnosis of this complication. Vnitrni lekarstvi 57(2):214–221PubMed

79.

Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT (2005) Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002–Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 23(36):9219–9226. https://doi.org/10.1200/jco.2005.03.2086 CrossRefPubMed

80.

Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4(6):379–398. https://doi.org/10.1038/sj.thj.6200312 CrossRefPubMed

81.

Misiani R, Tiraboschi G, Mingardi G, Mecca G (1987) Management of myeloma kidney: an anti-light-chain approach. Am J Kidney Dis 10(1):28–33CrossRefPubMed

82.

Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults (1984). Br Med J Clin Res ed 288 (6428):1411–1416

83.

Sanders PW (1994) Pathogenesis and treatment of myeloma kidney. J Lab Clin Med 124(4):484–488PubMed

84.

Heher EC, Goes NB, Spitzer TR, Raje NS, Humphreys BD, Anderson KC, Richardson PG (2010) Kidney disease associated with plasma cell dyscrasias. Blood 116(9):1397–1404. https://doi.org/10.1182/blood-2010-03-258608 CrossRefPubMedPubMedCentral

85.

Sanders PW, Herrera GA, Chen A, Booker BB, Galla JH (1988) Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Investig 82(6):2086–2096. https://doi.org/10.1172/jci113830 CrossRefPubMed

86.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R (2017) Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN 15(2):230–269CrossRef

87.

Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, Biour M, Massy Z (2005) Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 39(7–8):1194–1197. https://doi.org/10.1345/aph.1E589 CrossRefPubMed

88.

Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS (2010) Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther 6(1):31–35. https://doi.org/10.4103/0973-1482.63570 CrossRefPubMed

89.

Dietzek A, Connelly K, Cotugno M, Bartel S, McDonnell AM (2015) Denosumab in hypercalcemia of malignancy: a case series. J Oncol Pharm Pract 21(2):143–147. https://doi.org/10.1177/1078155213518361 CrossRefPubMed

90.

Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK (2014) Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99(9):3144–3152. https://doi.org/10.1210/jc.2014-1001 CrossRefPubMedPubMedCentral

91.

Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Mineral Res 27(7):1471–1479. https://doi.org/10.1002/jbmr.1613 CrossRef

92.

Cicci JD, Buie L, Bates J, van Deventer H (2014) Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leukemia 14(6):e207-211. https://doi.org/10.1016/j.clml.2014.07.005 CrossRef

93.

Sanders PW, Booker BB (1992) Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Investig 89(2):630–639. https://doi.org/10.1172/jci115629 CrossRefPubMed

94.

Bayraktar UD, Warsch S, Pereira D (2011) High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma. Am J Hematol 86(2):224–227. https://doi.org/10.1002/ajh.21922 CrossRefPubMed

95.

Arimura A, Li M, Batuman V (2006) Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107(2):661–668. https://doi.org/10.1182/blood-2005-03-1186 CrossRefPubMed

96.

Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78(5):773–785CrossRefPubMed

97.

Fudenberg HH, Virella G (1980) Multiple myeloma and Waldenstrom macroglobulinemia: unusual presentations. Sem Hematol 17(1):63–79

98.

Pruzanski W, Watt JG (1972) Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Report on 10 patients and a review of the literature. Ann Internal Med 77(6):853–860CrossRef

99.

Ying WZ, Allen CE, Curtis LM, Aaron KJ, Sanders PW (2012) Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J Clin Investig 122(5):1777–1785. https://doi.org/10.1172/jci46490 CrossRefPubMed

100.

Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N (2010) Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28(30):4635–4641. https://doi.org/10.1200/jco.2010.28.1238 CrossRefPubMed

101.

Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30(24):2946–2955. https://doi.org/10.1200/jco.2011.39.6820 CrossRefPubMed

102.

Mai EK, Bertsch U, Durig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29(8):1721–1729. https://doi.org/10.1038/leu.2015.80 CrossRefPubMed

103.

Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376(9758):2075–2085. https://doi.org/10.1016/s0140-6736(10)61424-9 CrossRefPubMed

104.

Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S (2010) Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer 116(13):3143–3151. https://doi.org/10.1002/cncr.25143 CrossRefPubMed

105.

Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J, Granell M, Besalduch J, Palomera L, Gonzalez Y, Etxebeste MA, Diaz-Mediavilla J, Hernandez MT, de Arriba F, Gutierrez NC, Martin-Ramos ML, Cibeira MT, Mateos MV, Martinez J, Alegre A, Lahuerta JJ, San Miguel J, Blade J (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120(8):1589–1596. https://doi.org/10.1182/blood-2012-02-408922 CrossRefPubMed

106.

Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M (2016) VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 127(21):2569–2574. https://doi.org/10.1182/blood-2016-01-693580 CrossRefPubMed

107.

Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM (2010) The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 116(16):3807–3814. https://doi.org/10.1002/cncr.25139 CrossRefPubMedPubMedCentral

108.

Specter R, Sanchorawala V, Seldin DC, Shelton A, Fennessey S, Finn KT, Zeldis JB, Dember LM (2011) Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. Eur Renal Assoc 26(3):881–886. https://doi.org/10.1093/ndt/gfq482 CrossRef

109.

Feest TG, Burge PS, Cohen SL (1976) Successful treatment of myeloma kidney by diuresis and plasmaphoresis. Br Med J 1(6008):503–504CrossRefPubMedPubMedCentral

110.

Misiani R, Remuzzi G, Bertani T, Licini R, Levoni P, Crippa A, Mecca G (1979) Plasmapheresis in the treatment of acute renal failure in multiple myeloma. Am J Med 66(4):684–688CrossRefPubMed

111.

Zucchelli P, Pasquali S, Cagnoli L, Ferrari G (1988) Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33(6):1175–1180CrossRefPubMed

112.

Johnson WJ, Kyle RA, Pineda AA, O’Brien PC, Holley KE (1990) Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Internal Med 150(4):863–869CrossRef

113.

Moist L, Nesrallah G, Kortas C, Espirtu E, Ostbye T, Clark WF (1999) Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. Am J Nephrol 19(1):45–50. doi:13424CrossRefPubMed

114.

Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN (2005) Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Annals of internal medicine 143(11):777–784CrossRefPubMed

115.

Cserti C, Haspel R, Stowell C, Dzik W (2007) Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 47(3):511–514. https://doi.org/10.1111/j.1537-2995.2006.01143.x CrossRefPubMed

116.

Movilli E, Guido J, Silvia T, Francesco S, Giovanni C (2007) Plasma exchange in the treatment of acute renal failure of myeloma. Nephrol Dial Transpl 22(4):1270–1271. https://doi.org/10.1093/ndt/gfl628 CrossRef

117.

Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL (2008) Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 73(11):1282–1288. https://doi.org/10.1038/ki.2008.108 CrossRefPubMed

118.

UpToDate (2017) Treatment and prognosis of kidney disease in multiple myeloma and other monoclonal gammopathies. https://www.uptodate.com/contents/treatment-and-prognosis-of-kidney-disease-in-multiple-myeloma-and-other-monoclonal-gammopathies?source=search_result&search=myeloma%20kidney%20treatment&selectedTitle=1~77

119.

Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH (2016) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: the seventh special issue. J Clin Apheresis 31(3):149–162. https://doi.org/10.1002/jca.21470 CrossRefPubMed

120.

Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR (2007) Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol JASN 18(3):886–895. https://doi.org/10.1681/asn.2006080821 CrossRefPubMed

121.

Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P (2009) Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol CJASN 4(4):745–754. https://doi.org/10.2215/cjn.04590908 CrossRefPubMed

122.

Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, Joly B, Peraldi MN, Arnulf B, Vigneau C, Lamy T, Wynckel A, Kolb B, Royer B, Rabot N, Benboubker L, Combe C, Jaccard A, Moulin B, Knebelmann B, Chevret S, Fermand JP (2017) Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. Jama 318(21):2099–2110. https://doi.org/10.1001/jama.2017.17924 CrossRefPubMedPubMedCentral

123.

Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, Cockwell P (2008) European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 9:55. https://doi.org/10.1186/1745-6215-9-55 CrossRefPubMedPubMedCentral

Title: Myeloma light chain cast nephropathy, a review
Authors: Insara Jaffer Sathick
Maria Eleni Drosou
Nelson Leung
Publication date: 01-04-2019
Publisher: Springer International Publishing
Published in: Journal of Nephrology / Issue 2/2019
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-018-0492-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Urinary IgM excretion: a reliable marker for adverse pregnancy outcomes in women with chronic kidney disease

Sodium removal by peritoneal dialysis: a systematic review and meta-analysis

Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3–4 chronic kidney disease

Beyond chronic kidney disease: the diagnosis of Renal Disease in the Elderly as an unmet need. A position paper endorsed by Italian Society of Nephrology (SIN) and Italian Society of Geriatrics and Gerontology (SIGG)

The assessment of cognitive function in older adult patients with chronic kidney disease: an integrative review

Nephrology in the global environment

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials